grant
The Role of Abnormal Inter-Organelle Communication in the Pathogenesis of Tauopathy
Organization RUTGERS, THE STATE UNIV OF N.J.Location PISCATAWAY, UNITED STATESPosted 1 Sept 2014Deadline 31 Dec 2029
NIHUS FederalResearch GrantFY2026(hydroxymethylglutaryl-CoA reductase (NADPH)) kinase5'-AMP-activated protein kinaseAD dementiaAD therapyAD treatmentAMP-activated kinaseAMP-activated protein kinaseAMPK enzymeAbscissionAccelerationAddressAgingAlzheimer Type DementiaAlzheimer beta-ProteinAlzheimer disease dementiaAlzheimer disease treatmentAlzheimer sclerosisAlzheimer syndromeAlzheimer treatmentAlzheimer'sAlzheimer's Amyloid beta-ProteinAlzheimer's DiseaseAlzheimer's amyloidAlzheimer's disease therapyAlzheimer's therapyAlzheimers DementiaAmentiaAmyloid (Aβ) plaquesAmyloid Alzheimer's Dementia Amyloid ProteinAmyloid Beta-PeptideAmyloid PlaquesAmyloid Protein A4Amyloid beta-ProteinAmyloid βAmyloid β-PeptideAmyloid β-ProteinAttenuatedAutophagocytosisAutophagosomeAxon TerminalsAβBrainBrain DiseasesBrain DisordersBrain Nervous SystemCell Communication and SignalingCell SignalingClinicalCognitive DisturbanceCognitive ImpairmentCognitive declineCognitive deficitsCognitive function abnormalCommunicationCoupledDefectDegenerative Neurologic DisordersDementiaDiseaseDisorderDisturbance in cognitionDrug TargetingDysfunctionEncephalonEncephalon DiseasesExcisionExhibitsExtirpationFTD dementiaFailureFrontal Temporal DementiaFrontotemporal DementiaFunctional disorderGAP ProteinsGTPGTPase-Activating ProteinsGuanosine TriphosphateHMG CoA reductase (NADPH) kinaseHMG CoA reductase kinaseHMG coenzyme A reductase (NADPH) kinaseHealthHydrolysisImpaired cognitionIn VitroIntracellular Communication and SignalingIntracranial CNS DisordersIntracranial Central Nervous System DisordersLinkLysosomesMT-bound tauMediatingMembraneMiceMice MammalsMicro-tubuleMicrotubulesMitochondriaModelingMolecularMotilityMurineMusNerve CellsNerve DegenerationNerve UnitNervous System Degenerative DiseasesNeural CellNeural Degenerative DiseasesNeural degenerative DisordersNeuritic PlaquesNeurocyteNeurodegenerative DiseasesNeurodegenerative DisordersNeurofibrillary TanglesNeurologic Degenerative ConditionsNeuron DegenerationNeuronsOrganellesOutcomePathogenesisPathogenicityPathologicPathologyPatientsPhysiopathologyPresynaptic Nerve EndingsPresynaptic TerminalsPrimary Senile Degenerative DementiaProteinsQuality ControlReceptor ProteinRemovalReportingRoleSenile PlaquesSignal TransductionSignal Transduction SystemsSignalingSurgical RemovalSynapsesSynapticSynaptic BoutonsSynaptic TerminalsSystemTauopathiesTestingTimeToxic effectToxicitiesVacuoleVesiclea beta peptideabetaamyloid betaamyloid beta plaqueamyloid-b plaqueamyloid-b proteinattenuateattenuatesautophagyaβ plaquesbeta amyloid fibrilbiological signal transductioncognitive defectscognitive dysfunctioncognitive losscored plaquedegenerative diseases of motor and sensory neuronsdegenerative neurological diseasesdiffuse plaquedrug developmentextracellularfront temporal dementiafrontal lobe dementiafrontotemporal lobar degeneration dementiafrontotemporal lobar dementiafrontotemporal lobe degeneration associated with dementiaguanosinetriphosphatase activating proteinhydroxymethylglutaryl-CoA-reductase kinasehyper-phosphorylated tauhyperphosphorylated tauimprovedin vivoinsightmembrane structuremicrotubule bound taumicrotubule-bound taumitochondrialmitochondrial dysfunctionmouse modelmurine modelnerve cell deathnerve cell lossneural degenerationneurodegenerationneurodegenerativeneurodegenerative illnessneurofibrillary degenerationneurofibrillary lesionneurofibrillary pathologyneurological degenerationneuron cell deathneuron cell lossneuron deathneuron lossneuronalneuronal cell deathneuronal cell lossneuronal deathneuronal degenerationneuronal lossneuropathologic tauneuropathological taunew drug targetnew druggable targetnew pharmacotherapy targetnew therapeutic targetnew therapy targetnovelnovel drug targetnovel druggable targetnovel pharmacotherapy targetnovel therapeutic targetnovel therapy targetoverexpressoverexpressionp-taup-τpathophysiologypharmacologicphospho-tauphospho-τphosphorylated taupost-translational modification of tauposttranslational modification of taupreventpreventingprimary degenerative dementiareceptorrelease factorresectionretrograde transportsenile dementia of the Alzheimer typesocial rolesoluble amyloid precursor proteinsynapsetangletargeted drug therapytargeted drug treatmentstargeted therapeutictargeted therapeutic agentstargeted therapytargeted treatmenttautau Proteinstau associated neurodegenerationtau associated neurodegenerative processtau driven neurodegenerationtau factortau induced degenerationtau induced neurodegenerationtau mediated neurodegenerationtau neurodegenerative diseasetau neuropathologytau pathologytau pathophysiologytau phosphorylationtau posttranslational modificationtau proteinopathytau related neurodegenerationtau-1tau-induced pathologytauopathic neurodegenerative disordertauopathytraffickingτ Proteinsτ phosphorylation
Description preview
PROJECT SUMMARY
Hyperphosphorylation and aggregation of microtubule-associated tau is a pathological hallmark of tauopathies,
which constitutes one of the two defining features of Alzheimer’s disease (AD). In AD, tau pathology correlates
with neuronal death and cognitive dysfunction better than amyloid plaques. Thus, understanding the pathogenic…
🔒
Start 7-day free trial — $29.99/mo →Full details available on the Agency plan
Unlock the complete grant description, eligibility criteria, contract value, evaluation details and apply link — plus alerts, pipeline tracking, and CSV export.
Agency Plan
7-day free trialUnlock procurement & grants
Upgrade to access active tenders from World Bank, UNDP, ADB and more — with email alerts and pipeline tracking.
$29.99 / month
- 🔔Email alerts for new matching tenders
- 🗂️Track tenders in your pipeline
- 💰Filter by contract value
- 📥Export results to CSV
- 📌Save searches with one click